What is Sangui Biotech International 3-Year ROIIC %?
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sangui Biotech International's 3-Year ROIIC % for the quarter that ended in Jun. 2022 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
SGBI's 3-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.455 * Ranked among companies with meaningful 3-Year ROIIC % only.
Sangui Biotech International 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sangui Biotech International's 3-Year ROIIC %
For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sangui Biotech International's 3-Year ROIIC % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sangui Biotech International's 3-Year ROIIC % falls into.
Sangui Biotech International 3-Year ROIIC % Calculation
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.139 (Jun. 2022) - -0.338 (Jun. 2019) )
/
( 0.798 (Jun. 2022) - 0.478 (Jun. 2019) )
=
0.199
/
0.32
=
62.19%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sangui Biotech International (OTCPK:SGBI) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sangui Biotech International 3-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Sangui Biotech International's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sangui Biotech International (Sangui Biotech International) Business Description
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGBI has been successfully added to your 